Stock of the Day - February 25, 2021

Natera (NTRA)

$412.56

+$3.77 (+0.9%)

Market Cap: $58.92B

About Natera

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Today's Trend

Natera, Inc. (NASDAQ: NTRA) has recently moved sharply higher and reached an all-time high as investors focused on regulatory progress for its Signatera cancer test. The stock was trading near its 52-week high, indicating strong market momentum.

Japan approves Signatera for bladder-cancer treatment decisions. Japan’s PMDA authorized Signatera as a companion diagnostic for muscle-invasive bladder cancer. The approval supports the test’s use in guiding treatment and strengthens Natera’s international commercial opportunity. Natera expects a commercial launch in Japan in 2027. Natera, Inc. - Signatera Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
The approval has been identified as the main catalyst behind NTRA’s recent rally. Multiple market reports cited the Japan authorization as investors’ reason for bidding the shares higher, reflecting optimism that broader adoption of Signatera can support future revenue growth. Why Is Natera (NTRA) Stock Soaring Today
Goldman Sachs maintained a Hold rating. The unchanged view provides a counterpoint to the bullish trading momentum and suggests the bank is not recommending additional upside exposure at current levels. Goldman Sachs Keeps Their Hold Rating on Natera (NTRA)

Overall, NTRA’s upward move is being driven by the strategic significance of the Japanese approval, although the commercial launch is not expected until 2027 and the stock’s elevated valuation leaves investors sensitive to execution and future growth expectations.

← Previous Stock of the Day Next Stock of the Day →

Natera (NTRA)

About Natera

Today's Trend

Recent News